Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

OSU biologist describes 'restoration ecology' approach toward patient health

OSU biologist describes 'restoration ecology' approach toward patient health

Researchers reveal potent new mechanism of action for treatment of IBD

Researchers reveal potent new mechanism of action for treatment of IBD

NIH commences first-in-human trial evaluating experimental treatment for Ebola

NIH commences first-in-human trial evaluating experimental treatment for Ebola

Comparative Analysis of a Complex Monoclonal Antibody

Comparative Analysis of a Complex Monoclonal Antibody

UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

Study identifies new biomarker for early lung cancer diagnosis

Study identifies new biomarker for early lung cancer diagnosis

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

New drug for migraine in the pipeline

New drug for migraine in the pipeline

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Innovative antibody delivery method could offer effective way to combat Ebola infection

Innovative antibody delivery method could offer effective way to combat Ebola infection

Highly sensitive ELISA method for analysis of CET in plasma samples

Highly sensitive ELISA method for analysis of CET in plasma samples

AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies

AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies

Extending dosing intervals makes common multiple sclerosis drug safer to use

Extending dosing intervals makes common multiple sclerosis drug safer to use

UAMS Myeloma Institute expert compiles new book on Castleman disease

UAMS Myeloma Institute expert compiles new book on Castleman disease

New TSRI study uncovers workings of first potential treatment for Marburg virus

New TSRI study uncovers workings of first potential treatment for Marburg virus

Adrenomedullin could serve as biomarker, therapeutic target in disorders caused by leaky blood vessels

Adrenomedullin could serve as biomarker, therapeutic target in disorders caused by leaky blood vessels

Two immunotherapy approaches for multiple myeloma show hope

Two immunotherapy approaches for multiple myeloma show hope

New first line combination therapy shows promising results in patients with advanced NSCLC

New first line combination therapy shows promising results in patients with advanced NSCLC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.